The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 01, 2014

Filed:

Feb. 21, 2011
Applicants:

Benjamin Wizel, San Diego, CA (US);

Karin Riedl, Krems, AT;

Karen Lingnau, Vienna, AT;

Ursula Schlosser, Uttendorf, AT;

Jürgen Wruss, Vienna, AT;

Robert Schlegl, Siegnenfeld, AT;

Michael Weber, Vienna, AT;

Christoph Reinisch, Siegenfeld, AT;

Ljubomir Paucz, Vienna, AT;

Christoph Klade, Wr. Neustadt, AT;

Jee Loon Look, Boyds, MD (US);

Christian Ruiz, Gaithersburg, MD (US);

Robert Seid, Chapel Hill, NC (US);

Inventors:

Benjamin Wizel, San Diego, CA (US);

Karin Riedl, Krems, AT;

Karen Lingnau, Vienna, AT;

Ursula Schlosser, Uttendorf, AT;

Jürgen Wruss, Vienna, AT;

Robert Schlegl, Siegnenfeld, AT;

Michael Weber, Vienna, AT;

Christoph Reinisch, Siegenfeld, AT;

Ljubomir Paucz, Vienna, AT;

Christoph Klade, Wr. Neustadt, AT;

Jee Loon Look, Boyds, MD (US);

Christian Ruiz, Gaithersburg, MD (US);

Robert Seid, Chapel Hill, NC (US);

Assignee:

Valneva Austria GmbH, Vienna, AT;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/39 (2006.01); A61K 9/14 (2006.01); A61K 9/51 (2006.01); A61K 39/40 (2006.01); A61K 39/42 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 9/51 (2013.01); A61K 39/40 (2013.01); A61K 39/42 (2013.01);
Abstract

The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKLKLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 μm.


Find Patent Forward Citations

Loading…